Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
Rhea-AI Summary
Kamada (NASDAQ: KMDA) will release its fiscal year and fourth quarter 2025 financial results on Wednesday, March 11, 2026 before U.S. markets open. Management will host an investor conference call at 8:30am Eastern Time the same day and will webcast the discussion live.
Investors may join by phone (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) using conference ID 13758519 or via the live webcast link provided by the company.
Positive
- None.
Negative
- None.
News Market Reaction – KMDA
In the Mar 4 session, KMDA gained 2.91%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Forward guidance | Positive | +5.8% | Issued 2026 revenue and adjusted EBITDA guidance with double-digit growth targets. |
| Dec 18 | Commercial contract | Positive | +2.9% | Announced $10–$14M extension of Canadian supply tender securing future sales. |
| Dec 08 | Trial discontinuation | Negative | -4.9% | Discontinued Phase 3 InnovAATe inhaled AAT trial after futility analysis. |
| Nov 10 | Earnings update | Positive | +5.4% | Reported strong Q3 and nine‑month 2025 results with >30% profitability growth. |
| Nov 04 | Clinical milestone | Positive | -3.2% | First patient enrolled in SHIELD CYTOGAM trial for CMV prevention in transplant. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has typically seen the stock move in the same direction as the apparent tone of the announcement, with only one divergence event in the last five releases.
Over the last several months, Kamada reported strong Q3 2025 results with double‑digit revenue and profitability growth, followed by positive commercial updates like a $10–$14 million Canadian tender extension and detailed 2026 revenue and EBITDA guidance. A negative clinical event occurred with the discontinuation of the InnovAATe Phase 3 inhaled AAT trial, while another release highlighted first‑patient enrollment in the CYTOGAM SHIELD trial. Today’s FY and Q4 2025 earnings date fits into this pattern of frequent operational and financial updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to Host Conference Call at 8:30am ET
REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March 11, 2026.
Kamada’s management will host an investment community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689- 8263 (International) using conference I.D. 13758519. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1751343&tp_key=e8c73d1516.
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
